Trials / Recruiting
RecruitingNCT05949931
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
A Randomized, Open, Multicenter Phase II Clinical Trial of Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma (PENAHL Study)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted to evaluate the safety and efficiency of Penpulimab combined with AVD in patients with newly- diagnosed advanced classic Hodgkin lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Concurrent penpulimab and AVD | Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle. |
| DRUG | Sequential penpulimab and AVD | Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle. |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2026-09-30
- Completion
- 2027-12-01
- First posted
- 2023-07-18
- Last updated
- 2024-08-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05949931. Inclusion in this directory is not an endorsement.